Why MiMedx Group Shares Imploded

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of MiMedx Group (NASDAQ: MDXG  ) , a manufacturer of patented regenerative biomaterial products (in essence, products designed to treat inflammation and help wounds heal), were eviscerated, falling as much as 70% at one point before recovering half of its losses after it announced the receipt of an untitled letter from the Food and Drug Administration alleging it does not possess the proper licensing to manufacture certain products.

So what: According to the FDA's untitled letter (note, an untitled letter is a notice of violation(s), but does not meet the threshold of a warning letter), because some of the products handled by MiMedx have been treated with a micronization process, they should be treated as drugs and therefore licensed by the FDA. Without the proper licenses, the assumption would be that MiMedx is unlawfully manufacturing some of its products.

Now what: It did not take long for MiMedx's management team to fire back, with COO and President Bill Taylor noting his surprise at the receipt of the letter and the company standing behind its full-year revenue guidance for 2013 and 2014. Although MiMedx's management does believe it's done everything to meet the pre-set guidelines, CEO Parker Petit noted that the company can alter its production to meet its revenue goals. MiMedx plans to meet with the FDA to determine the next course of action.

As of now this is a gigantic mess and the yellow caution tape should be flowing until further notice. On one hand, if MiMedx is found to be in the clear, then it could very easily recoup much of today's losses. Conversely, the confirmation of the receipt of an untitled letter solidifies the seriousness of these allegations and poses the potential to put a serious dent in MiMedx's revenue growth. Feel free to add it to your Watchlist, but I'd suggest keeping a distance in all walks from this stock until further notice.

MiMedx shares have been a dream stock for day-trader's today, but its implosion serves as a good reminder that the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2622455, ~/Articles/ArticleHandler.aspx, 12/22/2014 5:03:58 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement